Pulse Biosciences' (PLSE) "Sell (D-)" Rating Reiterated at Weiss Ratings

Pulse Biosciences (NASDAQ:PLSE - Get Free Report)'s stock had its "sell (d-)" rating reiterated by analysts at Weiss Ratings in a note issued to investors on Saturday,Weiss Ratings reports.

Separately, Oppenheimer started coverage on Pulse Biosciences in a research report on Monday, July 7th. They issued an "outperform" rating and a $22.00 price target on the stock. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $22.00.

Pulse Biosciences Stock Up 3.9%

NASDAQ:PLSE opened at $18.08 on Friday. Pulse Biosciences has a 12-month low of $13.77 and a 12-month high of $25.00. The firm has a market capitalization of $1.22 billion, a P/E ratio of -17.22 and a beta of 1.79. The stock's fifty day simple moving average is $16.96 and its 200-day simple moving average is $16.48.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.02).

Insider Activity at Pulse Biosciences

In related news, Director Robert W. Duggan bought 34,659 shares of the stock in a transaction that occurred on Wednesday, September 10th. The shares were acquired at an average price of $14.66 per share, with a total value of $508,100.94. Following the completion of the transaction, the director owned 47,551,200 shares in the company, valued at $697,100,592. The trade was a 0.07% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CTO Darrin Uecker sold 20,000 shares of Pulse Biosciences stock in a transaction dated Wednesday, September 17th. The shares were sold at an average price of $16.21, for a total value of $324,200.00. Following the completion of the sale, the chief technology officer directly owned 122,872 shares in the company, valued at approximately $1,991,755.12. This represents a 14.00% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 95,000 shares of company stock valued at $1,550,380. 74.60% of the stock is owned by insiders.

Institutional Trading of Pulse Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of America Corp DE increased its position in shares of Pulse Biosciences by 0.7% in the second quarter. Bank of America Corp DE now owns 783,536 shares of the company's stock valued at $11,824,000 after acquiring an additional 5,775 shares during the last quarter. Geode Capital Management LLC grew its holdings in Pulse Biosciences by 7.2% during the second quarter. Geode Capital Management LLC now owns 499,464 shares of the company's stock worth $7,538,000 after purchasing an additional 33,744 shares during the period. Westside Investment Management Inc. grew its holdings in Pulse Biosciences by 10.5% during the second quarter. Westside Investment Management Inc. now owns 64,290 shares of the company's stock worth $970,000 after purchasing an additional 6,135 shares during the period. Nuveen LLC bought a new position in Pulse Biosciences during the first quarter worth about $915,000. Finally, Panoramic Capital LLC grew its holdings in Pulse Biosciences by 8.5% during the first quarter. Panoramic Capital LLC now owns 52,723 shares of the company's stock worth $848,000 after purchasing an additional 4,152 shares during the period. Institutional investors and hedge funds own 76.95% of the company's stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.